Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Sarcoma and Rare Cancers Congress 2024

New EU pharma regulation

MCBS, ESCAT and evaluation of clinical benefit and molecular targets in MAs and HTA

Date

15 Mar 2024

Session

New EU pharma regulation

Topics

Translational Research;  Cancer Care Equity Principles and Health Economics;  Rare Cancers

Tumour Site

Presenters

Olli Tenhunen

Authors

O. Tenhunen

Author affiliations

  • Evaluation Of Medicines, Finnish Medicines Agency, 90220 - Oulu/FI

Resources

This content is available to ESMO members and event participants.
Login

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.